Tag Archives: Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL)

Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment